Kite Pharma (KITE) Tops Q3 EPS by 26c

Kite Pharma (NASDAQ: KITE) reported Q3 EPS of ($0.38), $0.26 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $4.09 million.

Kite's guidance remains unchanged. Kite expects to burn between $100 million and $125 million in cash for the full year 2015, which includes both operating expenses and capital expenditures. This guidance does not include cash inflows or outflows for business development activities.

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c